Search research articles
Contact Us
Filters
Showing results (21-30 of 283) with videos related to
Page
of 29
Sort By:
Blood Reviews
|
April 7, 2020
Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models
Roland B Walter, Elihu H Estey
Best Practice & Research. Clinical Haematology
|
June 18, 2019
Novel monoclonal antibody-based therapies for acute myeloid leukemia
Linde M Morsink, Roland B Walter
Current Hematologic Malignancy Reports
|
April 22, 2015
Update on antigen-specific immunotherapy of acute myeloid leukemia
Sarah A Buckley, Roland B Walter
Hematology. American Society of Hematology. Education Program
|
December 4, 2020
Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings
Anna B Halpern, Roland B Walter
Leukemia
|
June 27, 2024
Measurable residual disease in haematological and solid cancers
Roland B Walter, Robert Peter Gale
Cancers
|
December 8, 2020
Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
Utkarsh H Acharya, Roland B Walter
Oncotarget
|
December 20, 2018
CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia
Anna B Halpern, Roland B Walter
Cells
|
February 25, 2025
Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Margery Gang, Megan Othus, Roland B Walter
Blood
|
September 6, 2024
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old
Roland B Walter, Victoria Potter, Charles Craddock
Leukemia & Lymphoma
|
June 9, 2016
Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia
Kristen Pettit, Wendy Stock, Roland B Walter
Page
of 29
Search research articles
Search
Showing results (21-30 of 283) with videos related to
Sort By:
Page
of 29
Blood Reviews
|
April 7, 2020
Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models
Roland B Walter, Elihu H Estey
Best Practice & Research. Clinical Haematology
|
June 18, 2019
Novel monoclonal antibody-based therapies for acute myeloid leukemia
Linde M Morsink, Roland B Walter
Current Hematologic Malignancy Reports
|
April 22, 2015
Update on antigen-specific immunotherapy of acute myeloid leukemia
Sarah A Buckley, Roland B Walter
Hematology. American Society of Hematology. Education Program
|
December 4, 2020
Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings
Anna B Halpern, Roland B Walter
Leukemia
|
June 27, 2024
Measurable residual disease in haematological and solid cancers
Roland B Walter, Robert Peter Gale
Cancers
|
December 8, 2020
Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
Utkarsh H Acharya, Roland B Walter
Oncotarget
|
December 20, 2018
CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia
Anna B Halpern, Roland B Walter
Cells
|
February 25, 2025
Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Margery Gang, Megan Othus, Roland B Walter
Blood
|
September 6, 2024
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old
Roland B Walter, Victoria Potter, Charles Craddock
Leukemia & Lymphoma
|
June 9, 2016
Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia
Kristen Pettit, Wendy Stock, Roland B Walter
Page
of 29